9,731 Halozyme Therapeutics, Inc. $HALO Shares Sold by Boston Partners

Boston Partners reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 0.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,763,837 shares of the biopharmaceutical company’s stock after selling 9,731 shares during the quarter. Boston Partners owned about 2.42% of Halozyme Therapeutics worth $305,124,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Hilton Head Capital Partners LLC bought a new position in shares of Halozyme Therapeutics in the 3rd quarter worth $33,000. CoreCap Advisors LLC raised its position in shares of Halozyme Therapeutics by 98.0% during the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 150 shares in the last quarter. MidFirst Bank purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth $28,000. Finally, Quantbot Technologies LP bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth $30,000. 97.79% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of Halozyme Therapeutics from $95.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Friday, November 6th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 7th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Stifel Nicolaus set a $130.00 price target on Halozyme Therapeutics in a research note on Friday, October 16th. Finally, Leerink Partners lowered Halozyme Therapeutics from an “outperform” rating to a “hold” rating and lifted their price target for the stock from $110.00 to $117.00 in a research note on Friday, November 6th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has an average rating of “Hold” and a consensus price target of $108.18.

View Our Latest Stock Report on Halozyme Therapeutics

Halozyme Therapeutics Trading Down 0.2%

Shares of HALO stock opened at $95.80 on Thursday. The stock has a market capitalization of $10.92 billion, a PE ratio of 24.38, a P/E/G ratio of 0.36 and a beta of 0.92. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $134.00. The business has a 50-day moving average of $113.81 and a 200 day moving average of $85.87. The company has a debt-to-equity ratio of 13.50, a current ratio of 3.88 and a quick ratio of 3.60.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.09. The business had revenue of $492.97 million for the quarter, compared to analyst estimates of $491.63 million. Halozyme Therapeutics had a return on equity of 751.81% and a net margin of 26.93%. Halozyme Therapeutics’s revenue for the quarter was up 39.1% compared to the same quarter last year. During the same period last year, the company earned $1.72 EPS. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 8.34 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Matthew Posard sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $96.43, for a total value of $482,150.00. Following the transaction, the director owned 48,609 shares in the company, valued at approximately $4,687,365.87. This trade represents a 9.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $98.38, for a total transaction of $1,967,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at $75,534,196.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 149,226 shares of company stock valued at $15,744,643. Insiders own 2.50% of the company’s stock.

About Halozyme Therapeutics

(Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Read More

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.